The risks of prescribing pregabalin to patients already addicted to illicit drugs or alcohol almost always outweigh the benefits, therefore deprescribing pregabalin is usually appropriate. This article outlines safe and realistic protocols to reduce and stop pregabalin in patients with major addiction problems.
{"title":"Assisted withdrawal of pregabalin in drug and alcohol users","authors":"M. Bicknell, D. Rhinds","doi":"10.1002/psb.2061","DOIUrl":"https://doi.org/10.1002/psb.2061","url":null,"abstract":"The risks of prescribing pregabalin to patients already addicted to illicit drugs or alcohol almost always outweigh the benefits, therefore deprescribing pregabalin is usually appropriate. This article outlines safe and realistic protocols to reduce and stop pregabalin in patients with major addiction problems.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81927064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
While prescribed medicines are free for all in Scotland, Wales and Northern Ireland, patients in England who are not exempt still need to pay prescription charges. But in the current cost‐of‐living crisis, is the present system fair and might it actually represent a false economy for the NHS?
{"title":"Prescription charge controversies in England","authors":"Angela Dowden","doi":"10.1002/psb.2063","DOIUrl":"https://doi.org/10.1002/psb.2063","url":null,"abstract":"While prescribed medicines are free for all in Scotland, Wales and Northern Ireland, patients in England who are not exempt still need to pay prescription charges. But in the current cost‐of‐living crisis, is the present system fair and might it actually represent a false economy for the NHS?","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78715204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Getting to the heart of cardiovascular risk","authors":"","doi":"10.1002/psb.2059","DOIUrl":"https://doi.org/10.1002/psb.2059","url":null,"abstract":"","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80156929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Healthcare Quality Improvement Partnership (HQIP) CVDPREVENT audit was set up to monitor and support improvements in cardiovascular disease prevention in primary care in England. This article summarises the findings of its third annual audit report, which includes data up to March 2022.
{"title":"Summary of the third annual HQIP CVDPREVENT audit report","authors":"S. Chaplin","doi":"10.1002/psb.2064","DOIUrl":"https://doi.org/10.1002/psb.2064","url":null,"abstract":"The Healthcare Quality Improvement Partnership (HQIP) CVDPREVENT audit was set up to monitor and support improvements in cardiovascular disease prevention in primary care in England. This article summarises the findings of its third annual audit report, which includes data up to March 2022.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88261512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ethnic representation is an often‐overlooked element of early‐phase clinical trial design. This article discusses the factors underlying this issue and suggests measures that could be taken to promote greater inclusivity in trials.
{"title":"Ethnic and racial diversity in early‐phase trial design","authors":"E. Okenyi, L. Walker","doi":"10.1002/psb.2056","DOIUrl":"https://doi.org/10.1002/psb.2056","url":null,"abstract":"Ethnic representation is an often‐overlooked element of early‐phase clinical trial design. This article discusses the factors underlying this issue and suggests measures that could be taken to promote greater inclusivity in trials.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87209344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Technology: reflections on the past and future","authors":"","doi":"10.1002/psb.2051","DOIUrl":"https://doi.org/10.1002/psb.2051","url":null,"abstract":"","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74587618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dyslipidaemia is an important risk factor in the development of atherosclerotic cardiovascular disease in people with diabetes. This article discusses the lipid modifying therapies available, and the current evidence and guidance on their use in diabetes.
{"title":"Lipid modification in people with diabetes","authors":"D. Morris","doi":"10.1002/psb.2053","DOIUrl":"https://doi.org/10.1002/psb.2053","url":null,"abstract":"Dyslipidaemia is an important risk factor in the development of atherosclerotic cardiovascular disease in people with diabetes. This article discusses the lipid modifying therapies available, and the current evidence and guidance on their use in diabetes.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78628464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drovelis is a new combined oral contraceptive (COC) containing drospirenone and estetrol. This article discusses its dosing requirements, clinical trial efficacy and adverse effects.
{"title":"Drovelis: an oral contraceptive with drospirenone and estetrol","authors":"S. Chaplin","doi":"10.1002/psb.2057","DOIUrl":"https://doi.org/10.1002/psb.2057","url":null,"abstract":"Drovelis is a new combined oral contraceptive (COC) containing drospirenone and estetrol. This article discusses its dosing requirements, clinical trial efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83556767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gout is a condition that has been recognised for centuries but management is still often suboptimal. Angus Thompson explains how increasing patients’ understanding of the condition and its treatment can help improve outcomes.
{"title":"Time to take the heat out of gout","authors":"A. Thompson","doi":"10.1002/psb.2058","DOIUrl":"https://doi.org/10.1002/psb.2058","url":null,"abstract":"Gout is a condition that has been recognised for centuries but management is still often suboptimal. Angus Thompson explains how increasing patients’ understanding of the condition and its treatment can help improve outcomes.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86629431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Respiratory syncytial virus (RSV) infection remains a major public health problem, especially in younger children and the elderly. But several monoclonal antibodies, antivirals and vaccines, either recently launched or in development, offer new hope for RSV prevention and treatment.
{"title":"Respiratory syncytial virus: desperately seeking solutions","authors":"M. Greener","doi":"10.1002/psb.2055","DOIUrl":"https://doi.org/10.1002/psb.2055","url":null,"abstract":"Respiratory syncytial virus (RSV) infection remains a major public health problem, especially in younger children and the elderly. But several monoclonal antibodies, antivirals and vaccines, either recently launched or in development, offer new hope for RSV prevention and treatment.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"21 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83583024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：